When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is not well aligned with FDA’s authority to regulate drug safety and efficacy.

The executive order would require other countries to pay more for medications so that Americans could pay less. But experts aren’t sure it will work.

CMS said on Monday that it would announce a list of 15 drugs eligible for a third round of Medicare price negotiations by early February next year. For the first time, the list would include drugs payable under Medicare Part B - which covers medicines administered in a doctor's office or hospital - in addition to prescription drugs covered under Medicare Part D,

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the amount of Medicare spending subject to price negotiation by billions of dollars annually.

The editorial board of the Wall Street Journal is criticizing President Trump over an executive order expanding drug price controls. “For that trade we could have elected Democrats,”

A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the Medicare health insurance plan the power to negotiate lower drug prices.